Oncology Central

Immune play: defending the liver


The notable emergence of immunotherapy as an effective and durable anti-tumor treatment strategy is driving intense clinical research into new agents. The recent approval of the first anti-programmed death (PD)-1 antibody, pembrolizumab, by the US FDA in August 2014 for metastatic melanoma, has highlighted the increasingly dominant role that cancer immunotherapy agents play in the oncology therapeutic arsenal.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.